Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database
J. Vansteenkiste, C. Dooms, J. Vandebroek, K. Nackaerts, D. Galdermans, L. Bosquée, K. Deschepper, W. Van Kerckhoven, N. Dams (Leuven, Brussels, Belgium)
Source: Annual Congress 2002 - Thoracic oncology: diagnosis and prognosis
Session: Thoracic oncology: diagnosis and prognosis
Session type: Oral Presentation
Number: 3727
Disease area: Thoracic oncology
Abstract Purpose: Chemotherapy in advanced NSCLC yields a symptom control (SC) rate higher than the objective response rate. We previously reported the superior 'clinical-benefit response' when single agent Gemcitabine (GEM) was compared to Cisplatin-based combination chemotherapy (Ann Oncol 12:1221-1230, 2001). We now report the influence of treatment choice, age, performance status (PS), and treatment duration on SC. Method: Pts. received either GEM (1000mg/m2 , d1-8-15) or Cisplatin (100mg/m2 , d1) plus Vindesine (3mg/m2 , d1-15) (PV), both every 4 weeks. Scores of 9 symptoms were listed weekly by the pt. on visual analogue scales. Improvement of a symptom was defined as 2 consecutive cycles of improvement over baseline. Results: Baseline symptoms in the 169 pts. were well balanced between the 2 arms (84 GEM, 85 PV). Both pts. with objective response and disease stabilization had clearly better SC than those with progression. SC in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis. Compared to PV, a significantly larger number of GEM-pts. had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008). SC was very similar in younger (<65y) versus older (>=65y) pts., and only slightly better in those with a Karnofsky PS>=80% than in those <80%. Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only. Conclusion: Both treatments yield a SC rate much higher than expected by the objective response rate. SC was at least as good in the elderly group, was only slightly inferior in the Karnofsky PS=2 group, and was mainly achieved during the first 3 cycles of treatment, with further improvement thereafter in the GEM-arm only.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Vansteenkiste, C. Dooms, J. Vandebroek, K. Nackaerts, D. Galdermans, L. Bosquée, K. Deschepper, W. Van Kerckhoven, N. Dams (Leuven, Brussels, Belgium). Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database. Eur Respir J 2002; 20: Suppl. 38, 3727
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: